ASCO 2024 - Paul Burton
For Amgen, ASCO 2024 was all about lung cancer, with encouraging data in both non-small cell and small cell lung cancer. At the event in Chicago, editor-in-chief Jonah Comstock caught up with Amgen chief medical officer Dr Paul Burton to get the scoop on all the company’s recent research highlights.
They discuss new Phase 1B data around Lumakras (sotorasib), Amgen’s KRAS inhibitor in NSCLC and an ongoing phase 3 of Lumakras in colorectal cancer. And Burton reports on Imdeltra (tarlatamab-dlle), a bispecific T-cell engager, and its new promising data in small cell lung cancer, which tripled median survival.
Beyond the news, they discuss the trend of moving cancer treatments into earlier lines of therapy a bit and some of the advantages and challenges of that kind of innovation.
Finally, Burton shares a little bit about the company’s other bispecific Blincyto (blinatumomab), which recently secured a PDUFA date in just a few weeks.
Check out the whole discussion below.
